Purpurogallin carboxylic acid exhibits synergistic effects with 5‑fluorouracil on liver cancer cells <em>in vitro</em> by targeting ABCG2

Zhao,Pingping; Liu,Wei; Wang,Shuqing; Lun,Junjie

doi:10.3892/etm.2024.12564

Purpurogallin carboxylic acid exhibits synergistic effects with 5‑fluorouracil on liver cancer cells in vitro by targeting ABCG2

Authors:
- Pingping Zhao
- Wei Liu
- Shuqing Wang
- Junjie Lun
View Affiliations

Affiliations: Department of Oncology, Changle County People's Hospital Affiliated to Weifang Medical College, Weifang, Shandong 261000, P.R. China, Department of Traditional Chinese Medicine, Affiliated Hospital of Weifang Medical College, Weifang, Shandong 261000, P.R. China
Published online on: May 8, 2024 https://doi.org/10.3892/etm.2024.12564
Article Number: 276
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Purpurogallin carboxylic acid (PCA) is a natural phenol compound derived from Macleaya microcarpa (Maxim.) Fedde, which exerts particular antioxidant and anti‑inflammatory capacities. However, the effects and mechanisms of PCA on liver cancer cells remain unknown. Therefore, network pharmacology and computer virtual docking were used to identify the target‑proteins of PCA. In addition, surface plasmon resonance, protease activity and rhodamine excretion assays were carried out to evaluate the effects of PCA on the activity of ATP binding cassette subfamily G member 2 (ABCG2). The synergistic effects of PCA and 5‑fluorouracil (5‑FU) on liver cancer cell proliferation, cell cycle arrest, colony formation and spheroid formation abilities in vitro were determined by Cell Counting Kit‑8 (CCK‑8) assay, flow cytometry, western blot analysis, colony formation and spheroid formation assays, respectively. ABCG2 was identified as a potential target of PCA, with a high docking score. The equilibrium dissociation constant of PCA for ABCG2 protein was 1.84 µM, while the median inhibitory concentration of this protein was 3.09 µM. In addition, the results demonstrated that PCA could significantly reduce the drug efflux capacity of liver cancer cells. CCK‑8 assays revealed that liver cancer cell treatment with 10 µM PCA and 10 µM 5‑FU exhibited the most potent synergistic effects on liver cancer cell proliferation at 48 h. Additionally, cell co‑treatment with PCA and 5‑FU also significantly attenuated the colony and spheroid formation abilities of liver cancer cells in vitro, while it promoted their arrest at the G1 phase of the cell cycle. Furthermore, ABCG2 silencing in liver cancer cells notably abrogated the synergistic effects of PCA and 5‑FU. In conclusion, the present study demonstrated that PCA exhibited synergistic effects with 5‑FU on liver cancer cells in vitro via targeting ABCG2. Therefore, PCA combined with 5‑FU may be a potential strategy for liver cancer therapy.

View Figures

View References

1	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021.PubMed/NCBI View Article : Google Scholar
2	Chakraborty E and Sarkar D: Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel). 14(2798)2022.PubMed/NCBI View Article : Google Scholar
3	Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III trial. J Clin Oncol. 40:150–160. 2022.PubMed/NCBI View Article : Google Scholar
4	Ray EM and Sanoff HK: Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: Challenges and solutions. J Hepatocell Carcinoma. 4:131–138. 2017.PubMed/NCBI View Article : Google Scholar
5	Xu T, Guo P, Pi C, He Y, Yang H, Hou Y, Feng X, Jiang Q, Wei Y and Zhao L: Synergistic Effects of curcumin and 5-fluorouracil on the hepatocellular carcinoma in vivo and vitro through regulating the expression of COX-2 and NF-κB. J Cancer. 11:3955–3964. 2020.PubMed/NCBI View Article : Google Scholar
6	Dai W, Gao Q, Qiu J, Yuan J, Wu G and Shen G: Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. Tumour Biol. 37:6307–6313. 2016.PubMed/NCBI View Article : Google Scholar
7	Zeng LH and Wu TW: Purpurogallin is a more powerful protector of kidney cells than trolox and allopurinol. Biochem Cell Biol. 70:684–690. 1992.PubMed/NCBI View Article : Google Scholar
8	Zeng LH, Rootman DS, Burnstein A, Wu J and Wu TW: Morin hydrate: A better protector than purpurogallin of corneal endothelial cell damage induced by xanthine oxidase and SIN-1. Curr Eye Res. 17:149–152. 1998.PubMed/NCBI View Article : Google Scholar
9	Rambabu M and Jayanthi S: Virtual screening of national cancer institute database for claudin-4 inhibitors: Synthesis, biological evaluation, and molecular dynamics studies. J Cell Biochem. 120:8588–8600. 2019.PubMed/NCBI View Article : Google Scholar
10	Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J and Arabzadeh S: Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 214:118–123. 2018.PubMed/NCBI View Article : Google Scholar
11	Kodan A, Futamata R, Kimura Y, Kioka N, Nakatsu T, Kato H and Ueda K: ABCB1/MDR1/P-gp employs an ATP-dependent twist-and-squeeze mechanism to export hydrophobic drugs. FEBS Lett. 595:707–716. 2021.PubMed/NCBI View Article : Google Scholar
12	Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR and Valdameri G: Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 237(114346)2022.PubMed/NCBI View Article : Google Scholar
13	Chen YL, Chen PM, Lin PY, Hsiau YT and Chu PY: ABCG2 overexpression confers poor outcomes in hepatocellular carcinoma of elderly patients. Anticancer Res. 36:2983–2988. 2016.PubMed/NCBI
14	Kobayashi K, Higai K, Mukozu T, Matsui D, Amanuma M, Yoshimine N, Ogino Y, Matsui T, Wakui N, Shinohara M, et al: Tivantinib decreases hepatocyte growth factor-induced BCRP expression in hepatocellular carcinoma HepG2 cells. Biol Pharm Bull. 43:1421–1425. 2020.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S and Huang J: Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends. 16:31–45. 2022.PubMed/NCBI View Article : Google Scholar
17	Li S, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Chen Y, Li W and Yang J: p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma. Front Biosci (Elite Ed). 10:461–468. 2018.PubMed/NCBI View Article : Google Scholar
18	Liu X: ABC family transporters. Adv Exp Med Biol. 1141:13–100. 2019.PubMed/NCBI View Article : Google Scholar
19	Mao Q and Unadkat JD: Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J. 17:65–82. 2015.PubMed/NCBI View Article : Google Scholar
20	Han LW, Gao C and Mao Q: An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. Expert Opin Drug Metab Toxicol. 14:817–829. 2018.PubMed/NCBI View Article : Google Scholar
21	Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, Jiang G, Hou Y, Zhu Y, Han Y, et al: The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 11(10791)2021.PubMed/NCBI View Article : Google Scholar
22	Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W and Huang G: SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma. Biomed Pharmacother. 129(110315)2020.PubMed/NCBI View Article : Google Scholar
23	Lu P, Sun H, Zhang L, Hou H, Zhang L, Zhao F, Ge C, Yao M, Wang T and Li J: Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma. Mol Med. 18:1136–1146. 2012.PubMed/NCBI View Article : Google Scholar
24	Wei CT, Chen LC, Hsiang YP, Hung YJ, Chien PH, Pan HL and Chen YJ: Chrysin-induced ERK1/2 phosphorylation enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Anticancer Res. 39:695–701. 2019.PubMed/NCBI View Article : Google Scholar
25	Guo X, To KKW, Chen Z, Wang X, Zhang J, Luo M, Wang F, Yan S and Fu L: Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. J Exp Clin Cancer Res. 37(31)2018.PubMed/NCBI View Article : Google Scholar
26	Bharathiraja P, Yadav P, Sajid A, Ambudkar SV and Prasad NR: Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer. Drug Resist Updat. 71(101004)2023.PubMed/NCBI View Article : Google Scholar
27	Aung TN, Qu Z, Kortschak RD and Adelson DL: Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci. 18(656)2017.PubMed/NCBI View Article : Google Scholar
28	Zeng YP, Yang ZR, Guo XF, Jun W and Dong WG: Synergistic effect of puerarin and 5-fluorouracil on hepatocellular carcinoma. Oncol Lett. 8:2436–2442. 2014.PubMed/NCBI View Article : Google Scholar
29	Li F, Wang J, Wu N, Zhang H, Li Z and Wei N: H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. Biochem Biophys Res Commun. 520:93–98. 2019.PubMed/NCBI View Article : Google Scholar
30	Cao J, Huang J, Gui S and Chu X: Preparation, synergism, and biocompatibility of in situ liquid crystals loaded with sinomenine and 5-fluorouracil for treatment of liver cancer. Int J Nanomedicine. 16:3725–3739. 2021.PubMed/NCBI View Article : Google Scholar